drugset
drugset / Trial / NCT02269215

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

NCT02269215 ↗

Phase 1 Completed 73 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Safety, tolerability and pharmacokinetics of BIII 890

Timeline

Start
2000-01
Primary completion
2000-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Crobenetine Small molecule 31.25 mg Intravenous
Subject Crobenetine Small molecule 62.5 mg Intravenous
Subject Crobenetine Small molecule 120 mg Intravenous
Subject Crobenetine Small molecule 125 mg Intravenous

Indications

No indication recorded.